Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Adjuvant HT or chemotherapy choice should be offered to women with ER+ tumors
January 27th, 2005
Researchers with Cancer Research UK say that premenopausal women with estrogen receptor-positive breast tumors should be offered the choice of either adjuvant hormone therapy or chemotherapy. L. Fallowfield and colleagues conducted a study to determine the treatment preferences (adjuvant goserelin or cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy) of healthy premenopausal women should they hypothetically develop estrogen-receptor (ER) positive early breast cancer. They had 200 pre- or peri-menopausal women read two scenarios describing goserelin or chemotherapy. Information included: how and where treatments were administered,...
Source: Women's Health Weekly (2005-01-27)
|
